Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aspreva, Roche deal

ASV and ROG amended the royalty terms of a 2003 deal that granted ASV rights

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE